One Thirty Over Eighty: How America Lowered the Hypertension Line While Europe Held Steady

A single edit to a single table turned tens of millions of healthy Americans into patients overnight. The question is whether the line was drawn for them or for the people who bill them. In November of 2017, the American College of Cardiology and the American Heart Association released a clinical guideline that ran to roughly four hundred and eighty pages, and somewhere in the front matter they moved a single number. The threshold for diagnosing high blood pressure fell from 140/90 to 130/80. Nobody’s artery changed that day. No chest tightened, no vessel narrowed, no symptom appeared. And yet, by the arithmetic of that one revision, about thirty-one million Americans who had been healthy the previous evening were now classified as having a chronic cardiovascular disease. National prevalence of hypertension climbed from near thirty-two percent of adults to near forty-six percent between one edition of a document and the next, and among adults under forty-five the rate more than doubled. Nothing about the population’s arteries had changed; only the boundary of the word had moved.

A change that large invites a hard question, and it deserves to be asked without flinching: did the evidence require it, or did the revenue? Before that can be answered, the numbers themselves need correcting, because the popular shorthand gets them wrong. The figure 120/80 has marked the boundary of ideal pressure for decades, well before the 2017 panel convened. What moved was the line that separates “normal” from “sick.” Under the older American standard, and under the one Europe still uses, a person carried no diagnosis until the cuff read 140/90. The 2017 panel pushed that diagnostic line down to 130/80 and renamed the band from 120 to 129 as “elevated,” a category that had never before carried a warning. So the honest description runs like this: the territory in which an American is told nothing is wrong has shrunk to anything below 120/80, the disease line has dropped to 130/80, and Europe has declined to follow.

To understand why a number on a wall can be argued over like a border treaty, it helps to remember that for most of human history there was no number at all. Blood pressure as a measurable quantity is younger than the printing press by a wide margin, and the disease we call hypertension could not exist as a defined condition until someone built the instrument that defines it.

The instrument made the disease

The physiology came first. William Harvey described the circulation of the blood in 1628, establishing that the heart drives a closed loop rather than a tide. More than a century later, in 1733, an English clergyman named Stephen Hales performed the experiment usually credited as the first measurement of arterial pressure. He tied down a horse, opened an artery, and inserted a tall glass tube; the animal’s blood climbed more than eight feet and rose and fell with each heartbeat. The method killed the subject and helped no patient, yet it proved that the pressure of circulating blood was a real and quantifiable force. In the 1820s the French physician Jean-Léonard-Marie Poiseuille replaced the unwieldy column with a mercury manometer and gave medicine the millimeter-of-mercury unit, the mmHg still printed on every reading taken today.

The nineteenth century turned the measurement outward, away from the opened artery and toward the intact arm. Karl von Vierordt showed in 1855 that enough external pressure would obliterate the pulse, and he built a sphygmograph to record the pulse wave without breaking the skin; Étienne-Jules Marey made it portable a few years later. A British physician, Frederick Akbar Mahomed, used such a device to report something that reshaped the field: elevated pressure could exist in a person with healthy kidneys, which pried hypertension loose from the renal failure it had been assumed to accompany. In 1881 Samuel Siegfried Karl von Basch produced the first practical non-invasive sphygmomanometer, and in 1896 the Italian physician Scipione Riva-Rocci wrapped an inflatable cuff around the upper arm, the design every patient still recognizes. Riva-Rocci’s cuff could capture only the systolic peak, found by inflating until the wrist pulse vanished. The second number waited until 1905, when the Russian military surgeon Nikolai Korotkoff listened through a stethoscope as the cuff deflated and named the sounds that mark both the systolic and the diastolic pressure. Only at that moment did the familiar two-number reading exist. Hypertension is, in a real sense, a little over a century old as a diagnosable condition, because it could not be diagnosed before the tool that diagnoses it.

What came next should make anyone cautious about treating a threshold as settled truth. For the first half of the twentieth century, organized medicine regarded high blood pressure as harmless and, in older patients, even desirable. Paul Dudley White, the most prominent American cardiologist of his generation, taught that elevated pressure in the aging was necessary to push blood through stiffened vessels to the brain and kidneys, and that such patients should be left alone even if a treatment existed. Into the 1950s a reading below 200 over 100 was widely called mild and benign, and some physicians dismissed hypertensives as merely anxious. The term for pressure with no identifiable cause, “essential hypertension,” coined by the German physiologist Otto Frank in 1925, carried in that era an unfortunate double meaning, as though the elevation were essential to a patient’s survival rather than simply unexplained.

The cost of that doctrine is written in the medical record of Franklin Roosevelt. His pressure was documented as high when he was in his mid-fifties; in 1941, faced with a reading of 188 over 105, his physicians prescribed phenobarbital and massage. Through the war years the number climbed past 220 over 130 while he carried the Allied effort and sat at Yalta, and in April of 1945 he died of a massive cerebral hemorrhage at sixty-three. His cardiologist, Howard Bruenn, later wondered in print what the century might have looked like had the means to control such pressure existed in time. What Roosevelt received was simply the standard of care of his era, exercised on the most protected patient in the world, and that standard amounted to watchful neglect.

One institution had already reached the opposite conclusion, and it is worth noticing which one. Life insurance companies, which lose money when policyholders die early, had been refusing coverage to applicants with high blood pressure for years, having read the mortality tables and priced the danger long before the medical societies accepted it. Commerce understood the risk while medicine called it benign. The clinical proof arrived through Edward Freis, who in January of 1964 launched the Veterans Administration Cooperative Study, the first randomized, double-blind, placebo-controlled, multi-hospital drug trial conducted in cardiovascular medicine, enrolling five hundred and twenty-three men across seventeen VA hospitals. Its results, reported in 1967 for the most severe cases and in 1970 for moderate ones, showed plainly that lowering blood pressure with the new thiazide diuretics and companion drugs prevented strokes, heart failure, and death. The Framingham Heart Study, begun in 1948 under the National Heart Act passed three years after Roosevelt’s death, supplied the population evidence that pressure predicts catastrophe. From that foundation of mortality trials and actuarial tables, the thresholds began their long descent.

The 2017 decision, and the trial behind it

The descent reached its current floor on the strength of a single trial. In 2015, the Systolic Blood Pressure Intervention Trial, known as SPRINT, randomized high-risk patients to a systolic target below 120 or below 140 and found that the lower goal cut the rate of major cardiovascular events and death by roughly a quarter, a reduction driven heavily by fewer cases of heart failure. Investigators stopped the study early because the benefit looked decisive, and SPRINT became the empirical spine of the 2017 guideline. Its logic was straightforward and, on its face, humane: if aiming lower saves lives, the line should sit lower.

There is a complication in that reasoning, and it is technical rather than financial, which makes it harder to wave away. SPRINT did not measure blood pressure the way a nurse measures it in a crowded clinic. It used an automated device that took several readings while the patient sat alone and resting, a method that removes the jolt of a white coat in the room and reliably produces lower numbers, by several points, than a conventional rushed cuff reading. The trial’s own ambulatory substudy found that patients in the “below 120” group were walking around with an average daytime systolic near 126, a value that corresponds to a clinic reading at least ten points higher. When the 2017 panel wrote 130/80 into the definition, it declined to specify whether that number should be obtained by the careful automated method or the ordinary office method. The new American threshold may therefore not describe the same physical state the trial rewarded. A patient labeled hypertensive at a hurried 132 in a clinic hallway might have measured comfortably under the trial’s target had the reading been taken the way the trial took it. The threshold came down while the method for measuring against it stayed undefined.

Now to the suspicion that prompts this essay, which is that the American line was moved to sell drugs, office visits, electrocardiograms, and echocardiograms. The charge is partly right and partly wrong, and the parts matter. Take the drugs first. The relabeling created roughly thirty-one million new patients, yet it did not, by itself, prescribe much more medication, because the same panel wrote that there was insufficient evidence to treat low-risk people in the new 130-to-139 band with anything beyond diet, exercise, and weight loss. Roughly fifty million Americans were newly told to change their habits and take nothing. The pharmaceutical windfall, measured in fresh prescriptions, was modest next to the scale of the relabeling. The testing intuition lands closer to the mark. A newly diagnosed patient is supposed to receive an electrocardiogram and a panel of laboratory studies, with echocardiography reserved for selected cases, so each new label does trigger at least one billable test and a basic cardiac tracing, though not the universal cascade of imaging the suspicion imagines. Where the logic holds without qualification is the office visit itself. A diagnosis is a relationship, and a relationship inside a fee-for-service system is a recurring charge. The guideline further recommended out-of-clinic monitoring for the overwhelming majority of the newly flagged, with one analysis finding that more than nine in ten untreated adults now over the line qualified for home or ambulatory monitoring to rule out white-coat readings. So the accurate verdict on the money is narrower and more interesting than the slogan: the 2017 line works less as a machine for selling pills than as a machine for manufacturing patients, along with the monitoring, follow-up, and low-grade anxiety that attend them.

Why Europe held the line

The contrast with Europe is the most revealing fact in the whole matter, because the Europeans saw the same SPRINT data and chose a different settlement. The 2024 guideline of the European Society of Cardiology kept the diagnosis of hypertension at 140/90, exactly where the Americans abandoned it. It did add a treated category called “elevated” pressure, covering 120 to 139 systolic, but with a crucial difference in logic: a European in that band is offered medication only when a calculation of cardiovascular risk justifies it, so the reading by itself does not brand him as hypertensive. The European target for treated patients has come down toward 120 to 129 systolic, so the Atlantic divide is narrower in treatment than the headline numbers suggest. The 2023 guideline of the European Society of Hypertension leans further toward restraint at the margins, holding the diagnostic line at 140/90 and setting deliberately gentler goals for the old, accepting systolic pressures between 140 and 150 in patients past eighty rather than chasing a number that frail bodies tolerate poorly.

Set the two philosophies side by side. America’s approach is effective because a lower, continuous target nudges clinicians toward earlier action against a risk that does rise smoothly from pressures as low as 115 over 75, and because a single firm number is simple to teach and to audit across a vast and uneven health system. That same approach is not effective because it fuses two questions that should stay apart, the question of who is sick and the question of who benefits from treatment, and by fusing them at a low number it converts tens of millions of low-risk people into patients who gain little while carrying the labels, the premiums, the follow-up, and the worry. Europe’s approach is effective because it keeps the disease label honest, reserving the word hypertension for a pressure that has long predicted real harm, while still treating aggressively the individuals whose calculated risk warrants it. The European method is not effective because a risk calculation is harder to perform in a brief appointment than a glance at one threshold, and because leaving the over-eighties at 140 to 150 will, in some patients, miss a benefit a lower goal would have caught. Neither settlement comes free. What separates them is that the European one does not require relabeling half the adult population to do its work.

So, is the American number a scheme to enrich the people who treat blood pressure? The evidence refuses to support so clean a story, and three facts stand in its way. First, the biology is real: cardiovascular risk climbs with pressure, and SPRINT found benefit in driving it down for high-risk patients. Second, the threshold’s long history was built on mortality trials and insurance mathematics rather than marketing, as the work of Freis and the actuaries shows. Third, the immediate predecessor guideline, the 2014 report known as JNC 8, had raised the threshold for people over sixty to 150/90, the opposite of what a relentless profit motive would produce. A conspiracy that periodically loosens its own grip is not much of a conspiracy.

The defense ends there, and the prosecution has three facts of its own. First, the 2017 panel widened a disease definition in precisely the way medical reformers have warned against for years, expanding the labeled population well beyond the group with clear evidence of benefit. Second, the American Academy of Family Physicians, the body representing the doctors who manage most of this country’s blood pressure, refused to endorse the guideline, citing flaws in how it was built and the thin benefit of the lower target. Third, the structural beneficiaries of a lower line are exactly who they appear to be: a fee-for-service system that bills per encounter, a drug class already among the most prescribed on earth, and a monitoring and testing apparatus that grows with every new diagnosis. The guideline’s authors did build real safeguards against industry influence, walling their evidence reviewers off from company money, and that protection deserves acknowledgment. Even so, it cannot erase the incentive structure that surrounds the decision and profits from its result.

The fair conclusion is uncomfortable for both camps. The American threshold is defensible as biology and questionable as honest labeling, and the European refusal to follow proves that a less commercially convenient line was available to anyone willing to draw it. Every diagnosis is also a transfer of authority, moving power from the person who feels fine to the institutions that will now measure, medicate, monitor, and bill him. When a single edit to a single table turns nearly half a nation’s adults into patients overnight, the people who drew the line owe the rest of us a plain accounting of whom the line was meant to serve. Europe, holding at 140 over 90, has at least left that question where it belongs: with the patient and the evidence rather than the invoice.